Print

Was MedImmune (AZN) Worth $15.6 Billion?  
8/6/2012 7:34:16 AM

The Washington region's biotechnology industry hit a fever fitch five years ago this summer after a series of acquisitions, including when British drug maker AstraZeneca shelled out $15.6 billion for Gaithersburg-based MedImmune, The Washington Post reported.

The deal at the time left some in the industry celebrating the large sticker price and others wondering if MedImmune was really worth that much. Five years later, the jury may still be out. While AstraZeneca has made MedImmune the hub of its biologics division, plying it with additional scientists and resources, a blockbuster drug that could justify the purchase price has yet to come to market.


//-->